Results 31 to 40 of about 16,542 (247)
JEADV Clinical Practice, 2023 Background In a recent post hoc analysis of multinational clinical trial data, dupilumab treatment for patients with moderate or severe atopic dermatitis (AD) reduced all‐cause and AD‐related hospitalisations.
Ken Igawa +6 more
doaj +1 more source
Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis [PDF]
, 2018 Olabola Awosika,1 Lori Kim,2 Momina Mazhar,2 Monica Rengifo-Pardo,1,2 Alison Ehrlich1,2 1Department of Dermatology, The George Washington Medical Faculty Associates, Washington, DC, USA; 2George Washington University School of Medicine & Health ...
Awosika O +4 more
core +2 more sources
Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis
American Journal of Ophthalmology Case Reports, 2020 Purpose: To describe a case of corneal ulceration associated with dupilumab use for atopic dermatitis. Observations: A patient developed an inflammatory corneal ulcer 3 weeks after starting bi-weekly intravenous dupilumab therapy.
Gavin Li +2 more
doaj +1 more source
Clinical-economic analysis of the target therapy in severe atopic dermatitidis in adults
Качественная клиническая практика, 2022 Target therapy of severe atopic dermatitidis (AD) is actual because AD has a high prevalence and social-economic burden. Target therapy consists of monoclonal antibodies (dupilumab) as well as janus kinase inhibitors (upadacitinib and baricitinib).
A. S. Kolbin +3 more
doaj +1 more source
Journal of Cutaneous Immunology and Allergy, 2023 Objectives Alopecia areata (AA) often coexists with atopic dermatitis (AD). Recently, several reports suggested that dupilumab, an interleukin 4 receptor α‐antagonist, administration could be a promising medication not only for severe AD but also for AA ...
Masahiro Fukuyama +3 more
doaj +1 more source
Dupilumab for recalcitrant Kimura disease
, 2022 Dupilumab for recalcitrant Kimura ...
Querzoli, Giulia +9 more
core +1 more source
Psoriasis appearing after dupilumab therapy in atopic dermatitis: A case report
SAGE Open Medical Case Reports, 2020 A 36-year-old Caucasian female with a long history of atopic dermatitis presented with multiple flares eventually leading to dupilumab therapy. Five months into the dupilumab therapy, she presented with well-demarcated erythematous plaques with silvery ...
Ho Seung Kim, Jensen Yeung
doaj +1 more source
BMC Pulmonary Medicine, 2023 Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a form of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis characterized by eosinophil-rich granulomatous inflammation and small-to-medium vessel vasculitis associated ...
Isao Suzaki +6 more
doaj +1 more source
Achieving clinical and histologic remission with tezepelumab in an adolescent with refractory eosinophilic gastrointestinal disease: A case report [PDF]
JPGN RepAbstract Tezepelumab is a human monoclonal antibody that binds to human thymic stromal lymphopoietin (TSLP), an epithelial cytokine that plays a role in Type 2 signaling. We describe a 17‐year‐old with a history of eosinophilic esophagitis (EoE) and eosinophilic gastroenteritis who demonstrated response to tezepelumab with both clinical and histologic ...
Newsome D +3 more
europepmc +2 more sources
Pustular Psoriasis in a Patient Treated with Dupilumab for Atopic Dermatitis: A Case Report
, 2023 Li Liu,* Jie Chen,* Kangheng Tang, Feng Li, Si Li, Xiaojie Ding Department of Dermatology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan Province, People’s Republic of China*These authors contributed equally to this ...
Tang K +5 more
core